Lead Product(s): TDI01
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TDI01
Highest Development Status: Phase I Product Type: Small molecule
Deal Size: $517.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 23, 2021
The agreement grants development and commercialization rights for TDI01 to Graviton in all territories, excluding China.